Researchers at the University of Copenhagen – The Faculty of Health and Medical Sciences found that activating a specialized group of neurons within the brainstem of mice restored full movement function in mice with symptoms of Parkinson’s disease.
The CEO of Maryland-based Novavax believes U.S. Emergency Use Authorization (EUA) for the company’s protein-based COVID-19 vaccine could happen “within weeks.”
In the face of Delta, the actual efficacy of Covid-19 vaccines in a real-world setting has come into question even if they still appear to be very close to 100 percent at preventing death or severe disease, which is the primary goal of a vaccine. Studies suggest that Moderna’s Covid-19 vaccine appears better than the Pfizer-BioNTech vaccination in terms of antibody count and prevention of hospitalizations, and both were significantly more effective than Johnson & Johnson’s shot.
The Pfizer/BioNTech Covid-19 vaccine showed 90.7 percent efficacy against the coronavirus in a clinical trial of children 5 to 11 years old, the U.S. drugmaker said on Oct. 22.
CureVac’s Covid-19 vaccine was 48 percent effective in the final analysis of the company’s pivotal mass trial, only marginally better than the 47 percent reported after an initial read-out two weeks earlier.
Novavax Inc. said vaccine efficacy appeared to be preserved in those receiving an approved influenza vaccine along with the company’s Covid-19 vaccine candidate compared to those receiving its Covid-19 vaccine alone.
The U.S. Food and Drug Administration granted marketing clearance for Ryplazim as the first FDA-approved therapy for the treatment of patients with the plasminogen deficiency type 1 (hypoplasminogenia), a rare genetic disorder.
China’s CanSino Biologics Inc. said the efficacy rate for the company’s single-dose Covid-19 vaccine may fall over time although it should still have a rate of 50 percent or more five to six months after inoculation.
Novavax Inc.’s Covid-19 vaccine was 96 percent effective in preventing cases caused by the original version of the coronavirus in a late-stage trial conducted in the United Kingdom, the company said on March 11, moving it a step closer to regulatory approval.
The results are in from Johnson & Johnso’s global Phase III ENSEMBLE clinical trial, and the company’s single-shot vaccine is 66% effective overall in preventing moderate-to-severe Covid-19, 28 days after vaccination.
